Alkermes plc. Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31)
Alkermes plc. (ALKS) reported Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) of $627.00 thousand for the 12-month period ending 2012-03-31, per its 10-K filed 2012-05-18.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecrease · last filed 2012-05-18
- Alkermes plc. other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $259.00K.
- Alkermes plc. other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $27.00K.
- Alkermes plc. other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was -$188.00K, a 141.50% decline year-over-year.
- Alkermes plc. other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $529.00K.
- Alkermes plc. other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for fiscal 2012 was $627.00K, a 65.44% increase from fiscal 2011.
- Alkermes plc. other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for fiscal 2011 was $379.00K, a 87.74% decline from fiscal 2010.
- Alkermes plc. other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for fiscal 2010 was $3.09M.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-05-18 | $286.00K derived: sum of 2 quarters · filed 2012-05-18 | $98.00K derived: sum of 3 quarters · filed 2012-05-18 | $627.00K 10-K · filed 2012-05-18 |
| 2011-12-31 | $27.00K 10-Q · filed 2012-02-02 | -$161.00K derived: sum of 2 quarters · filed 2012-02-02 | $368.00K 10-Q · filed 2012-02-02 | $316.00K derived: sum of 4 quarters · filed 2012-05-18 |
| 2011-09-30 | -$188.00K 10-Q · filed 2011-11-03 | $341.00K 10-Q · filed 2011-11-03 | $289.00K derived: sum of 3 quarters · filed 2012-05-18 | -$227.00K derived: sum of 4 quarters · filed 2012-05-18 |
| 2011-06-30 | $529.00K derived: 10-K 12 month − 3 quarters · filed 2012-05-18 | $477.00K derived: sum of 2 quarters · filed 2012-05-18 | -$39.00K derived: sum of 3 quarters · filed 2012-05-18 | $414.00K derived: sum of 4 quarters · filed 2012-05-18 |
| 2011-03-31 | -$52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-05-18 | -$568.00K derived: sum of 2 quarters · filed 2012-05-18 | -$115.00K derived: sum of 3 quarters · filed 2012-05-18 | $379.00K 10-K · filed 2012-05-18 |
| 2010-12-31 | -$516.00K 10-Q · filed 2012-02-02 | -$63.00K derived: sum of 2 quarters · filed 2012-02-02 | $431.00K 10-Q · filed 2012-02-02 | |
| 2010-09-30 | $453.00K 10-Q · filed 2011-11-03 | $947.00K 10-Q · filed 2011-11-03 | ||
| 2010-03-31 | $3.09M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |